GD patients are at increased risk of developing Parkinsonian symptoms, and this eventually led to the clinical observation that even carriers of heterozygous pathogenic GBA1 mutations are prone to manifesting PD [4,5,6,7]. This evidence concerns the gene GBA1 and Parkinson disease.